Aim: Blockade of EGFR by EGFR tyrosine kinase inhibitors such as erlotinib is insufficient for effective treatment of human pancreatic cancer due to independent activation of the Akt pathway, while amiloride, a potassium-sparing diuretic, has been found as a potential Akt inhibitor. The aim of this study was to investigate the anticancer effects of combined amiloride with erlotinib against human pancreatic cancer cells in vitro. Methods: Cell proliferation, colony formation, cell cycle and apoptosis were analyzed in 4 human pancreatic cancer cell lines Bxpc-3, PANC-1, Aspc-1 and CFPAC-1 treated with erlotinib or amiloride alone, or in their combination. The synergistic analysis for the effects of combinations of amiloride and erlotinib was performed using Chou-Talalay's combination index isobolographic method. Results: Amiloride (10, 30, and 100 µmol/L) concentration-dependently potentiated erlotinib-induced inhibition of cell proliferation and colony formation in the 4 pancreatic cancer cell lines. Isobolographic analysis confirmed that combinations of amiloride and erlotinib produced synergistic cytotoxic effects. Amiloride significantly potentiated erlotinib-induced G 0 /G 1 cell-cycle arrest and apoptosis in Bxpc-3 and PANC-1 cells. Amiloride inhibited EGF-stimulated phorsphorylation of AKT, and significantly enhanced erlotinib-induced downregulation of phorsphorylation of EGFR, AKT, PI3K P85 and GSK 3β in Bxpc-3 and PANC-1 cells. Conclusion: Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Treatment of pancreatic cancer patients with combination of erlotinib and amiloride merits further investigation.
Introduction
Pancreatic cancer is one of the most refractory cancers, with a 5-year survival of less than 6%. In 2013, this disease was the fourth leading cause of cancer deaths overall, and it was responsible for approximately 38 500 deaths in the United States [1] . Although surgical resection is the only known cure for pancreatic cancer, 80% of patients are diagnosed with advanced-stage disease, which includes metastatic or locally advanced cancers [2] . Therefore, less than 20% of people with pancreatic cancer have disease that can be surgically removed at the time of diagnosis. Gemcitabine or gemcitabine-based regimens are the standard chemotherapy in patients with advanced metastatic disease [3, 4] . Erlotinib (OSI-774, Tarceva, OSI Pharmaceuticals/Genentech), an oral small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was the first FDAapproved targeting agent for use in combination with gemcitabine in the management of pancreatic cancer. Miyabayashi et al demonstrated that erlotinib could increase gemcitabine efficacy by inhibiting the gemcitabine-induced up-regulation of the MAPK pathway in a pancreatic tumor model [5] . Patients with advanced pancreatic cancer who were treated with the combination of erlotinib and gemcitabine had a statistically significant survival advantage over patients treated with gemcitabine alone. However, the erlotinib plus gemcitabine regimen only slightly prolonged the one-year survival rate from 17% to 23% compared with gemcitabine alone [6] . Hence, there remains an urgent medical need to find more effective therapeutic approaches to treat this deadly disease.
Aberrant overactivation of the EGFR signaling pathway has been implicated in several cellular processes contributing to cancer progression, including cell proliferation, survival, angiogenesis, invasion and metastasis [7] . However, blockade of EGFR by EGFR TKIs is insufficient for effective treatment of human pancreatic cancer. Over activation of EGFR downstream signaling through the PI3K/AKT, Ras/Raf/MAPK, www.chinaphar.com Zheng YT et al Acta Pharmacologica Sinica npg and Jak/STAT pathways can have similar functions that lead to cell growth and survival by bypassing normal EGFR regulation. Mutations in K-Ras are found in approximately 61% of pancreatic cancers, leading to EGFR-independent activation of the PI3K/AKT and MEK/ERK pathways [8] . Therefore, dual blockage of EGFR and its downstream signaling might be a rational strategy for pancreatic cancer chemotherapy.
In non-small-cell lung cancer (NSCLC), it has been well documented that overactivation of AKT is secondary to activation of the c-met pathway. Inhibition of the PI3K/AKT pathway by blocking Met or using a PI3K inhibitor restores HGFinduced mechanisms of EGFR-TKI resistance to NSCLC [9, 10] . Similarly, inhibition of the PI3K/AKT pathway also potentiated the cytotoxicity of EGFR-TKIs in breast cancer cells [11, 12] . These findings suggest that simultaneous inhibition of the EGFR and PI3K/AKT pathways may be an effective therapeutic strategy to enhance erlotinib sensitivity in pancreatic cancers with aberrant PI3K/AKT signaling.
Amiloride is one of the most prescribed oral potassiumsparing diuretics used in the management of hypertension and congestive heart failure. It acts on epithelial sodium channels and is usually well tolerated at normal doses. Several studies have suggested its potential anti-cancer role because of its ability to induce apoptosis in various cancer cells in association with inactivation of PI3K/AKT and its downstream survival pathway [13, 14] . In addition, amiloride augmented TRAILinduced tumor cell apoptosis through AKT inactivation [15] . These studies indicate that amiloride may have the potential to cure tumors with aberrant overactivation of the PI3K/AKT pathway.
Based on these findings, we attempted to exploit the anticancer interaction between erlotinib and amiloride in a panel of human pancreatic cancer cell lines, which may provide a novel therapeutic strategy for combination chemotherapy in pancreatic cancer. This is the first study to report that amiloride can sensitize pancreatic cancer cells to the EGFR TKI erlotinib through the inhibition of PI3K/AKT signaling.
Materials and methods

Drugs and reagents
Amiloride hydrochloride was obtained from the National Institutes for Food and Drug Control (Beijing, China) and prepared in DMSO to obtain a 50 mmol stock solution. Erlotinib hydrochloride, LY294002, and BKM120 were purchased from Selleck Chemicals (Houston, TX) and dissolved in DMSO as a stock solution at 10 mmol. Aliquots were stored at -20 °C, and a working solution was freshly diluted with PBS before use.
Anti Cell viability assay Cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded in 96-well plates at a density of 5000-10 000 cells/well and allowed to grow for 24 h. They were then exposed to various concentrations of amiloride, erlotinib, or their combinations for 48 h. The IC 50 values at which the proliferation was reduced by 50% compared with the untreated control were calculated using nonlinear regression by GraphPad Prism 3.0 (GraphPad software, San Diego, CA, USA). Synergism analysis for the combination effects of amiloride and erlotinib was performed using Chou-Talalay's combination index isobolographic method using CompuSyn Version 1.0 software (ComboSyn, Inc, Paramus, NJ, USA) [16] .
Colony formation assays
The long-term anti-cancer effect was assessed by determining the ability of pancreatic cancer cells to form colonies after drug treatment. Cells were plated on six-well plates (1000-2000 cells/well) containing 2 mL complete culture medium, incubated for 48 h, and then treated with 0.5% DMSO (control), amiloride, erlotinib, or their combinations. After 10-15 d, the medium was removed, and the colonies in each well were stained with Giemsa solution (Sigma Chemical Co, St Louis, CA, USA), photographed and counted.
Cell cycle analysis
Exponentially growing cells were seeded in six-well plates and treated with amiloride (30 µmol/L) and erlotinib (3 µmol/L) alone or in combination for 12, 24, or 48 h. Cells were collected 
Western blotting
After exposure to 0.5% DMSO, amiloride, erlotinib or the combination of amiloride and erlotinib, the cells were washed twice in ice-cold PBS and lysed in 1×NuPAGE ® LDS sample buffer (Invitrogen, Carlsbad, CA, USA). The samples were then boiled for 10 min and centrifuged briefly. Samples were subjected to 10% SDS-PAGE and then transferred to a PVDF membrane. The membranes were then blocked with 5% nonfat milk and incubated with specific primary antibodies at 4 °C overnight. The membranes were washed and incubated with secondary HRP-conjugated antibodies. The membranes were washed again and detected using a chemiluminescence system according to the manufacturer's instructions (Immobilon TM Western chemiluminescent HRP substrate, Millipore Corporation, Billerica, MA, USA).
Statistical analysis
All data were from at least three independent experiments and are expressed as mean±SD. One-way ANOVA followed by S-N-K multiple comparisons was used to determine the differences among groups. The level of significance was set at P<0.05.
Results
Amiloride enhanced the growth inhibition of erlotinib in a panel of human pancreatic cancer cell lines The molecular profiles of the pancreatic cancer cell lines used in this study were obtained from the Sanger Institute (http:// www.sanger.ac.uk/). Table 1 summarizes the histologic and molecular characteristics and the sensitivity of erlotinib and amiloride for the four pancreatic cancer cell lines. Because all the cell lines harbor wild-type EGFR, the anticancer effect of erlotinib was minor and resulted in IC 50 values above 50 µmol/L. Amiloride mono-treatment also exerted minor anticancer activity against the tested cells, with IC 50 values >100 µmol/L in all cases. Although previous studies reported the anti-cancer activity of amiloride in a panel of tumor cell lines, the results here indicated that pancreatic cancer cells had a relatively low in vitro sensitivity to amiloride.
We therefore sought to determine whether the combination of erlotinib and amiloride would overcome the resistance observed with erlotinib treatment alone. The viability of Bxpc-3, PANC-1, Aspc-1, and CFPAC-1 pancreatic cancer cells treated with amiloride (10, 30, and 100 µmol/L), erlotinib (3, 10, and 30 µmol/L), or their combination was determined by the MTT assay ( Figure 1A) . Amiloride (10, 30 , and 100 µmol/L) significantly enhanced the erlotinib-induced inhibition of tumor cell growth in a concentration-dependent manner in a heterogeneous group of pancreatic cancer cell lines, including one harboring a wild-type K-Ras (Bxpc-3), two lines with a K-Ras G12D mutation (PANC-1 and Aspc-1), and another cell line harboring a K-Ras G12V mutation (CFPAC-1). We also analyzed the interaction between amiloride and erlotinib using Chou-Talalay's synergism analysis, a widely used method to analyze the synergy interaction in combination therapies. Interestingly, synergistic drug activity was observed from the normalized isobolograms for drug combinations in all cell lines tested ( Figure 1B) . We also assessed the long-term anti-cancer effects of combination treatment on cell viability by clonogenic assays, as shown in Figure 2 . The combination of amiloride and erlotinib resulted in a significant inhibition of colony formation in all the cell lines when compared with erlotinib alone. Taken together, these data revealed that amiloride enhanced the short-term and longterm growth inhibition of erlotinib in a panel of human pancreatic cancer cell lines independent of K-Ras status. Phase-specific cyclin D1 was also determined after 24 h of exposure by immunoblotting in parallel experiments. As shown in Figure 3C , concurrent administration of erlotinib and amiloride inhibited the expression of cyclin D1 to an increased extent compared with erlotinib treatment alone, consistent with G 1 -phase arrest. These data provide evidence that amiloride and erlotinib act synergistically to induce cell cycle arrest in G 1 phase, which may explain the synergistic interaction of amiloride and erlotinib in pancreatic cancer.
To determine whether apoptotic cell death was responsible for the synergistic cytotoxicity of amiloride and erlotinib, we performed flow cytometry analysis with Annexin V and PI staining. Cells were treated with amiloride, erlotinib, or their combination for 48 h. The results showed that the apoptosis rates of the amiloride plus erlotinib treatments in Bxpc-3 and PANC-1 cells were significantly increased compared with erlotinib treatment alone ( Figure 4A and 4B ). In addition, the combination of erlotinib and amiloride enhanced the expression of cleaved poly (ADP-ribose) polymerase (PARP) (p85) to a greater extent compared with erlotinib treatment alone ( Figure 4C ), thus confirming the synergistic apoptotic activity of the drug combination.
Amiloride promoted the sensitivity of erlotinib through inhibition of the EGFR/PI3K/AKT signaling pathway We further investigated the mechanism by which amiloride sensitized pancreatic cancer cells to erlotinib. First, we examined the impact of amiloride on the EGFR pathway. As indicated in Figure 5 , amiloride caused an obvious inhibition of EGF-simulated phosphorylation of AKT in a dose-dependent manner, while it showed no effects on phospho-ERK in all four pancreatic cancer cells. Amiloride also showed slight inhibition of phospho-EGFR in Bxpc-3 and PANC-1 cells, but not in Aspc-1 and CFPAC-1 cells.
Next, we investigated the combination effects of erlotinib and amiloride on the EGFR signaling pathway after 12 h of drug exposure. In Bxpc-3 and PANC-1 cells, the down-regulation of phospho-EGFR, phospho-AKT (Ser 473), phospho-AKT (Thr 308), phospho-PI3K P85, and p-GSK 3β by erlotinib was significantly potentiated by co-administration with amiloride ( Figure 6 ). However, combinational use of amiloride and erlotinib promoted down regulation of pho-ERK and PTEN in Bxpc-3 cells but not in PANC-1 cells. Collectively, these data indicate that at least one of the mechanisms of potentiation of erlotinib by amiloride is related to its inhibition of the EGFR/ PI3K/AKT pathway, but not the MEK/MAPK pathway. In npg addition, we also investigated the effects of two PI3K inhibitors on the cell growth inhibition induced by erlotinib. As illustrated in Figure 7 , both LY294002 and BKM120 showed obvious synergistic interaction with erlotinib, which indicates that the PI3K/AKT signaling pathway plays a critical role in the synergistic anti-cancer effects of amiloride and erlotinib.
Discussion
Amiloride has been widely used in the clinic as an oral potassium-sparing diuretic drug and is usually well tolerated at normal doses. Our results demonstrate for the first time that amiloride could synergize with erlotinib in various pancreatic cancer cell lines. These data provide a new promise for an old drug that may be used effectively in combination cancer therapies. Interestingly, the sensitization observed was independent of the mutation status of the K-Ras gene. Previous studies demonstrated that the K-Ras mutation can be regarded as a negative predictor of anti-EGFR agents in colorectal cancer [17] [18] [19] [20] . In addition, K-Ras mutations were found to be present in approximately 61% of pancreatic [21] . Thus, this combinational use of erlotinib and amiloride could particularly benefit pancreatic cancer patient subgroups that have little response to erlotinib monotherapy independent of K-Ras status.
The dependency of tumor cells on EGFR signaling for growth and survival is an important determinant of sensitivity to EGFR TKI monotherapy. A previous study revealed that amiloride may have the potential to inhibit EGFR phosphorylation [22] . Our studies supported that the combination of amiloride and erlotinib caused a significant inhibition of the EGFR/PI3K/AKT pathway compared with erlotinib alone. Up-regulation of phospho-AKT plays a pivotal role in tumor cell resistance to erlotinib [23] , and previous studies showed that inhibition of PI3K/AKT activity correlates with sensitivity to EGFR-TKIs in NSCLC cells [24] [25] [26] . Therefore, the addition of amiloride or agents that down-regulate EGFR/ PI3K/AKT signaling may provide promise for improving the therapeutic efficacy of erlotinib in resistant tumor cells.
Many other studies have attempted to conquer pancreatic cancer treatment through dual blockage of EGFR and its downstream signaling. Diep et al reported that combination treatments with erlotinib and MEK inhibitors RDEA119 or AZD6244 had significant synergistic effects only in pancreatic cancer cells with wild-type K-Ras but not in cells with mutant K-Ras [27] . Amiloride was found to potentiate the growth inhibition of erlotinib in all the selected pancreatic cancer cell lines independent of K-Ras gene status. Considering the high incidence of K-Ras gene mutations in pancreatic cancer, dual blockage of EGFR and PI3K/AKT may be a better choice to treat this deadly disease.
Erlotinib causes cell growth arrest in G 1 phase and subsequently induces apoptosis in a variety of tumor cells in vitro and in vivo [28] . We showed that amiloride also induced G 1 phase arrest in Bxpc-3 cells, which was synergistic with erlotinib. In PANC-1 cells, amiloride and erlotinib alone failed to cause G 1 -phase arrest, but the cells were obviously arrested in G 1 phase when treated with the combination of amiloride and erlotinib. Combination treatment of amiloride and erlotinib down regulated cyclin D1 in both Bxpc-3 and PANC-1 cells. Cyclin D1 was demonstrated to be a critical downstream effector of mutant EGFR signaling [29] . Previous studies indicated that gefitinib-sensitive cell lines showed G 1 cell cycle arrest and inactivation of downstream signaling proteins, while resistant cell lines had no changes in NSCLC cells [30] . Therefore, reduction of cyclin D1 expression may be a sensitivity marker for the EGFR-TKI response. Our results indicate that cyclin D1 is down-regulated by amiloride through the suppression of GSK-3β signaling, resulting in G 1 arrest and subsequent apoptosis. Collectively, these data suggest that the sensitizing effects of erlotinib by amiloride may be mediated via the cell cycle regulatory signaling pathway.
In conclusion, our study reported for the first time that amiloride can sensitize pancreatic cancer cells to erlotinib through down-regulation of the EGFR/PI3K/AKT pathway. Moreover, amiloride or other agents that modulate PI3K/AKT signaling may be useful therapeutic options for use in combination with erlotinib in pancreatic cancer patients. This new therapeutic strategy merits further investigation.
